TNB-486

TNB-486
Monoclonal antibody
Type	?
Target	CD19, CD3
Clinical data
Other names	AZD0486
Identifiers
UNII	3QW12I37H1;

TNB-486 (also known as AZD0486)^[1] "is a novel CD19x CD3 bispecific T-cell engager (TCE) that incorporates a unique anti-CD3 moiety designed to reduce cytokine release syndrome by binding to T-cells with low affinity".^[2] The drug is developed for cancer by AstraZeneca since its acquisition of TeneoTwo in 2022.^[3]^[4]^[5]

References[edit]

^ "AZD 0486 - AdisInsight". adisinsight.springer.com. Retrieved 19 November 2023.
^ Hou, Jing-Zhou; Jacobs, Ryan; Cho, Seok-Goo; Devata, Sumana; Gaballa, Sameh; Yoon, Dok Hyun; Stevens, Don A.; Kim, Jin Seok; Buelow, Ben; Nair, Ranjit (15 November 2022). "Interim Results of the Phase 1 Study of Tnb-486, a Novel CD19xCD3 T-Cell Engager, in Patients with Relapsed/Refractory (R/R) B-NHL". Blood. 140 (Supplement 1): 1474–1475. doi:10.1182/blood-2022-166385.
^ "AstraZeneca to acquire TeneoTwo and its clinical-stage T-cell engager, strengthening haematological cancer pipeline". Retrieved 19 November 2023.
^ Nair, Ranjit; Jacobs, Ryan; Cho, Seok-Goo; Devata, Sumana; Gaballa, Sameh; Yoon, Dok Hyun; Stevens, Don A.; Kim, Jin Seok; Shah, Nirav Niranjan; Brennan, Denise Marie; Law, Jason; Chen, Rob; Forcina, Alessandra; Buelow, Ben; Hou, Jing-Zhou (1 June 2023). "High complete response rate with TNB-486 in relapsed/refractory follicular lymphoma: Interim results from an ongoing phase 1 study". Journal of Clinical Oncology. 41 (16_suppl): 7524. doi:10.1200/JCO.2023.41.16_suppl.7524. S2CID 259079121.
^ Malik-Chaudhry, Harbani K.; Prabhakar, Kirthana; Ugamraj, Harshad S.; Boudreau, Andrew A.; Buelow, Benjamin; Dang, Kevin; Davison, Laura M.; Harris, Katherine E.; Jorgensen, Brett; Ogana, Heather; Pham, Duy; Schellenberger, Ute; Van Schooten, Wim; Buelow, Roland; Iyer, Suhasini; Trinklein, Nathan D.; Rangaswamy, Udaya S. (2021). "TNB-486 induces potent tumor cell cytotoxicity coupled with low cytokine release in preclinical models of B-NHL". mAbs. 13 (1): 1890411. doi:10.1080/19420862.2021.1890411. ISSN 1942-0862. PMC 8023237. PMID 33818299.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[1] "AZD 0486 - AdisInsight". adisinsight.springer.com. Retrieved 19 November 2023.

[2] Hou, Jing-Zhou; Jacobs, Ryan; Cho, Seok-Goo; Devata, Sumana; Gaballa, Sameh; Yoon, Dok Hyun; Stevens, Don A.; Kim, Jin Seok; Buelow, Ben; Nair, Ranjit (15 November 2022). "Interim Results of the Phase 1 Study of Tnb-486, a Novel CD19xCD3 T-Cell Engager, in Patients with Relapsed/Refractory (R/R) B-NHL". Blood. 140 (Supplement 1): 1474–1475. doi:10.1182/blood-2022-166385.

[3] "AstraZeneca to acquire TeneoTwo and its clinical-stage T-cell engager, strengthening haematological cancer pipeline". Retrieved 19 November 2023.

[4] Nair, Ranjit; Jacobs, Ryan; Cho, Seok-Goo; Devata, Sumana; Gaballa, Sameh; Yoon, Dok Hyun; Stevens, Don A.; Kim, Jin Seok; Shah, Nirav Niranjan; Brennan, Denise Marie; Law, Jason; Chen, Rob; Forcina, Alessandra; Buelow, Ben; Hou, Jing-Zhou (1 June 2023). "High complete response rate with TNB-486 in relapsed/refractory follicular lymphoma: Interim results from an ongoing phase 1 study". Journal of Clinical Oncology. 41 (16_suppl): 7524. doi:10.1200/JCO.2023.41.16_suppl.7524. S2CID 259079121.

[5] Malik-Chaudhry, Harbani K.; Prabhakar, Kirthana; Ugamraj, Harshad S.; Boudreau, Andrew A.; Buelow, Benjamin; Dang, Kevin; Davison, Laura M.; Harris, Katherine E.; Jorgensen, Brett; Ogana, Heather; Pham, Duy; Schellenberger, Ute; Van Schooten, Wim; Buelow, Roland; Iyer, Suhasini; Trinklein, Nathan D.; Rangaswamy, Udaya S. (2021). "TNB-486 induces potent tumor cell cytotoxicity coupled with low cytokine release in preclinical models of B-NHL". mAbs. 13 (1): 1890411. doi:10.1080/19420862.2021.1890411. ISSN 1942-0862. PMC 8023237. PMID 33818299.

[1]

[2]

[3]

[4]

[5]